Tristan Richard Gordon Sillars
Geschäftsführer bei Arquer Diagnostics Ltd.
Aktive Positionen von Tristan Richard Gordon Sillars
| Unternehmen | Position | Beginn | Ende |
|---|---|---|---|
Arquer Diagnostics Ltd.
 Arquer Diagnostics Ltd. Medical/Nursing ServicesHealth Services Arquer Diagnostics Ltd. develops proprietary diagnostic immunoassays for the detection of prostate and bladder cancer using urine samples. Its develops non-invasive, urine-based ELISA and Point-of Care tests meet the increased demand for cost-effective healthcare technologies that not only enhance patient care but help to reduce overall healthcare costs by improving patient outcomes. The firm will commercialise ELISA and point-of-care urine tests for prostate and bladder cancer for use in the urology clinic, hospital lab and the GP’s surgery. The company was founded by David Nicholas Miller-Jones and William Dawson in 2007 and is headquartered in Sunderland, the United Kingdom. | Direktor/Vorstandsmitglied | - | - |
| Geschäftsführer | - | - | |
| Finanzdirektor/CFO | - | - |
Karriereverlauf von Tristan Richard Gordon Sillars
Ehemalige bekannte Positionen von Tristan Richard Gordon Sillars
| Unternehmen | Position | Beginn | Ende |
|---|---|---|---|
| KPMG Transaction Services Group | Corporate Officer/Principal | - | - |
Statistik
International
| Vereinigtes Königreich | 3 |
Operativ
| Director/Board Member | 1 |
| Chief Operating Officer | 1 |
| Director of Finance/CFO | 1 |
Sektoral
| Health Services | 2 |
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Unternehmensverbindungen
| Private Unternehmen | 2 |
|---|---|
Arquer Diagnostics Ltd.
Arquer Diagnostics Ltd. Medical/Nursing ServicesHealth Services Arquer Diagnostics Ltd. develops proprietary diagnostic immunoassays for the detection of prostate and bladder cancer using urine samples. Its develops non-invasive, urine-based ELISA and Point-of Care tests meet the increased demand for cost-effective healthcare technologies that not only enhance patient care but help to reduce overall healthcare costs by improving patient outcomes. The firm will commercialise ELISA and point-of-care urine tests for prostate and bladder cancer for use in the urology clinic, hospital lab and the GP’s surgery. The company was founded by David Nicholas Miller-Jones and William Dawson in 2007 and is headquartered in Sunderland, the United Kingdom. | Health Services |
| KPMG Transaction Services Group |
